SCHEMBL4286963

SCHEMBL4286963

CC(C)(CC(=O)O)CC(F)(F)F

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.50
FFAR1 O14842 1/20 0.50
CPT2 P23786 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
HMGCR P04035 1/20 0.46
CHRM1 P11229 1/20 0.46
TBXA2R P21731 1/20 0.46
ADRA1A P35348 1/20 0.46
CYP2C19 P33261 2/20 0.44
HIF1A Q16665 2/20 0.44
CYP2D6 P10635 1/20 0.44
TSHR P16473 1/20 0.44
ACLY P53396 2/20 0.38
ALDH1A1 P00352 1/20 0.35
BHMT Q93088 3/20 0.34
FFAR3 O14843 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL557257 0.84 KDM4E (0.59) KDM4EFFAR1CPT2TDP1HMGCR
SCHEMBL12808778 0.81 KDM4E (0.56) KDM4EFFAR1CPT2TDP1HMGCR
SCHEMBL433760 0.79 KDM4E (0.54) KDM4EFFAR1CPT2TDP1HMGCR
SCHEMBL21272609 0.78 HMGCR (0.64) KDM4EFFAR1CPT2TDP1HMGCR
SCHEMBL48109 0.78 KDM4E (0.65) KDM4EFFAR1CPT2TDP1HMGCR
SCHEMBL30854909 0.78 KDM4E (0.65) KDM4EFFAR1CPT2TDP1HMGCR
Methane SCHEMBL371521 0.77 KDM4E (0.52) KDM4EFFAR1CPT2TDP1HMGCR
SCHEMBL17187568 0.77 KDM4E (0.52) KDM4EFFAR1CPT2TDP1HMGCR
SCHEMBL1979018 0.77 KDM4E (0.52) KDM4EFFAR1CPT2TDP1HMGCR
SCHEMBL11439787 0.75 KDM4E (0.62) KDM4EFFAR1CPT2TDP1HMGCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2061470-A2 HALOALKYL-SUBSTITUTED PYRIMIDINONE DERIVATIVES Neurogen Corporation (US) 2009-05-27 EP disclosed
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives NEUROGEN CORPORATION (US) 2008-04-17 US disclosed
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives NEUROGEN CORPORATION (US) 2008-04-17 US disclosed
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives NEUROGEN CORPORATION (US) 2008-04-17 US disclosed
WO-2008024433-A2 HALOALKYL-SUBSTITUTED PYRIMIDINONE DERIVATIVES NEUROGEN CORPORATION (US) 2008-02-28 WO disclosed
WO-2008024433-A2 HALOALKYL-SUBSTITUTED PYRIMIDINONE DERIVATIVES NEUROGEN CORPORATION (US) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080090845-A1 Haloalkyl-substituted pyrimidinone derivatives PIGS, GPR174, GPR17 KDM4E 3957/4885FFAR1 44/4885CPT2 4101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.